Chidamide for Patients With Recurrent and Metastatic Epstein-Barr Virus (EBV)-Associated Solid Tumors

Experimental Tumor Clinical Trial

Official title:
Study of Chidamide as a Single-agent Treatment for Patients With Recurrent and Metastatic Epstein-Barr Virus (EBV)-Associated Solid Tumors

Status Not yet recruiting

Clinical Trial Summary

Study of Chidamide as a Single-agent Treatment for Patients With Recurrent and Metastatic Epstein-Barr virus (EBV)-associated Solid Tumors

Clinical Trial Description

Chidamide，a novel histone deacetylase inhibitor has been approved for the treatment of relapsed or refractory peripheral T-cell lymphoma in China. The aim of this study was to observe the efficacy and safety of Chidamide as a single-agent treatment in patients with recurrent and metastatic Epstein-Barr virus (EBV)-associated solid tumors. ;

Study Design

Related Conditions & MeSH terms

Experimental Tumor

Clinical Trial Details

NCT number	NCT03494634
Study type	Interventional
Source	Sun Yat-sen University
Contact	Li Zhang, MD
Phone	86-20-87343458
Email	zhangli6@mail.sysu.edu.cn
Status	Not yet recruiting
Phase	Phase 2
Start date	April 15, 2018
Completion date	September 30, 2020

View Details

See also
	Status	Clinical Trial	Phase
	Not yet recruiting	`NCT03611231` - Chidamide Maintenance After Autologous Hematopoietic Stem Cell Transplantation for Relapsed, Refractory or High-risk Lymphoma	Phase 2
	Recruiting	`NCT03617432` - Chidamide Combined With CHOPE Regimen for Peripheral T-cell Lymphoma Patients	Phase 2